Iruplinalkib after surgery for early-stage ALK-positive lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests whether taking Iruplinalkib pills after lung cancer surgery can lower the risk of cancer returning in people with stage IA ALK-positive non-small cell lung cancer that has high-risk features.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older
- You have been diagnosed with stage IA non-small cell lung cancer (tumor 3 cm or smaller) that is ALK-positive (a specific gene change)
- Your cancer was removed by surgery (sublobar resection, lobectomy, or sleeve resection)
- You have not been treated with an ALK-targeted therapy before
- Your overall health is good (able to care for yourself and expected to live at least 12 weeks)
- Your blood counts and organ function are within certain limits
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tracks people with advanced ALK-positive lung cancer who are taking or will start Iruplinalkib. It checks how well Iruplinalkib works in the real world and monitors safety.
This trial tests lorlatinib as a treatment before surgery for people with a type of lung cancer called non-small cell lung cancer that has an ALK gene change (ALK-positive). The goal is to understand why some tumors respond and others may not, using advanced genetic tests.
This trial tests whether taking Iruplinalkib before surgery can help people with ALK-positive non-small cell lung cancer (NSCLC) that has not spread too far. The goal is to see if the drug shrinks the tumor enough for successful removal.
This real-world study looks at how effective Iruplinalkib is for people with ALK-positive non-small cell lung cancer. It is open to patients who have already taken this drug, and will simply collect data from your regular medical care.
This trial is for people with advanced lung cancer whose tumors have an ALK gene change and who have already taken a medicine called lorlatinib. It tests a new drug, iruplinalkib, to see how well it works for those who stopped responding to or couldn't tolerate lorlatinib.
This trial tests a new targeted pill (Iruplaltinib) combined with chemotherapy before surgery for patients with a specific type of lung cancer (ALK-positive non-squamous NSCLC). The goal is to shrink the tumor to make surgery more successful and potentially improve outcomes. This approach is called neoadjuvant therapy, meaning it's given before the main treatment (surgery).
Hear when a new NSCLC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.